YEMASSEE, SOUTH CAROLINA / ACCESS Newswire / January 21, 2026 / Alpha Genesis Inc., the largest nonhuman primate breeding and...
ATLANTA, GEORGIA / ACCESS Newswire / January 21, 2026 / As people across the country set health goals for the...
- Single Phase 2/3 Adaptive Study Design -- Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire...
Marks the company’s third consecutive placement as a Leader following recognition as highest in execution in 2023 and furthest in...
Figure 1 Human Continuum Inc. Appoints Dr. Tsun “Sean” Law, MD, MBA as its Chief Executive Officer. New York, N.Y.,...
~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~ SAN DIEGO, CALIFORNIA / ACCESS...
Company Unveils Seven AI Solutions for 2026, Built for The New Era of Healthcare MarketingCAMPBELL, Calif. and NEW YORK, Jan....
New streamlined, mobile-optimized shopping experience, allows consumers to purchase BUZZ BOMB™ directly, access exclusive promotions and engage with the brand...
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate...
Peer-Reviewed Paper Confirms Cavadex Drives Plummeting Coronary Artery Calcium Scores : Reversing the Irreversible ROBINA AND QUEENSLAND, AUSTRALIA / ACCESS...
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for...
Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record...
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused...
BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building...
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10...
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613...
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan....
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with...
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company,...
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding...